Clinical Research Directory
Browse clinical research sites, groups, and studies.
A Phase I/II Multiple Center Trial of 4SCAR19 Cells in the Treatment of Relapsed and Refractory B Cell Malignancies
Sponsor: Shenzhen Geno-Immune Medical Institute
Summary
The study will evaluate safety and efficacy of a 4th generation chimeric antigen receptor gene-modified T cells targeting CD19 (4SCAR19) for patients with B cell malignancies. Clinical response and development of a standardized lentiviral vector and cell production protocol will be investigated. This is a phase I/II trial enrolling patients from multiple clinical centers.
Key Details
Gender
All
Age Range
6 Months - Any
Study Type
INTERVENTIONAL
Enrollment
200
Start Date
2025-05-01
Completion Date
2029-12-31
Last Updated
2025-09-08
Healthy Volunteers
No
Conditions
Interventions
Therapeutic 4SCAR19 cells
Autologous 4th generation withdrawal lentiviral-transduced 4S CAR-T19
Locations (2)
Shenzhen Geno-immune Medical Institute
Shenzhen, Guangdong, China
The First People's Hospital of Yunnan
Kunming, Yunnan, China